Language:

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

The New England journal of medicine, 2020-01, Vol.382 (3), p.244-255 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1905239 ;PMID: 31893580

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Author: Tsimikas, Sotirios ; Karwatowska-Prokopczuk, Ewa ; Gouni-Berthold, Ioanna ; Tardif, Jean-Claude ; Baum, Seth J ; Steinhagen-Thiessen, Elizabeth ; Shapiro, Michael D ; Stroes, Erik S ; Moriarty, Patrick M ; Nordestgaard, Børge G ; Xia, Shuting ; Guerriero, Jonathan ; Viney, Nicholas J ; O’Dea, Louis ; Witztum, Joseph L
Subjects: Adult ; Aged ; Antisense drugs ; Antisense oligonucleotides ; Aorta ; Aortic stenosis ; Apolipoproteins ; Blood platelets ; Blood pressure ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - drug therapy ; Cholesterol - blood ; Control ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug dosages ; Drug therapy ; Female ; Health aspects ; Health risk assessment ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypolipidemic Agents - administration & dosage ; Hypolipidemic Agents - adverse effects ; Hypolipidemic Agents - therapeutic use ; Influenza ; Laboratories ; Least-Squares Analysis ; Lipoprotein A ; Lipoprotein(a) - blood ; Low density lipoprotein ; Male ; Middle Aged ; Oligonucleotides - administration & dosage ; Oligonucleotides - adverse effects ; Patients ; Risk Factors ; Stenosis ; Testing ; Urine
Is Part Of: The New England journal of medicine, 2020-01, Vol.382 (3), p.244-255
Description: Elevated levels of lipoprotein(a) in the plasma are a risk factor for cardiovascular disease, and lowering levels can be achieved with antisense oligonucleotide targeting LPA messenger RNA, which encodes lipoprotein(a). This trial tested whether the same effect can be achieved in persons with established cardiovascular disease.
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1905239
PMID: 31893580
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1905239 ;PMID: 31893580

Searching Remote Databases, Please Wait